Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$21.70M-$21.70MN/M vs Q3 2023 EPS Diluted-$0.35-$0.35N/M vs Q3 2023 Operating Income-$25,126,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,091,000N/M ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end